13,981 Shares in United Therapeutics Corporation $UTHR Purchased by Persistent Asset Partners Ltd

Persistent Asset Partners Ltd acquired a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the 2nd quarter, Holdings Channel reports. The fund acquired 13,981 shares of the biotechnology company’s stock, valued at approximately $7,575,000. United Therapeutics comprises about 2.3% of Persistent Asset Partners Ltd’s investment portfolio, making the stock its 7th largest holding.

Several other large investors also recently added to or reduced their stakes in the stock. Arjuna Capital lifted its stake in shares of United Therapeutics by 2.8% in the 1st quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock valued at $393,000 after purchasing an additional 18 shares during the last quarter. Sage Rhino Capital LLC boosted its holdings in shares of United Therapeutics by 5.1% in the 1st quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock worth $281,000 after purchasing an additional 23 shares during the period. Bryn Mawr Trust Advisors LLC increased its position in shares of United Therapeutics by 5.4% during the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock valued at $276,000 after purchasing an additional 24 shares during the last quarter. Meeder Advisory Services Inc. increased its position in shares of United Therapeutics by 4.1% during the 1st quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock valued at $392,000 after purchasing an additional 26 shares during the last quarter. Finally, Independent Advisor Alliance increased its position in shares of United Therapeutics by 3.3% during the 4th quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock valued at $406,000 after purchasing an additional 27 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

United Therapeutics Price Performance

UTHR opened at $499.73 on Monday. The business has a fifty day moving average of $535.95 and a 200 day moving average of $536.15. United Therapeutics Corporation has a 52-week low of $302.19 and a 52-week high of $609.35. The stock has a market cap of $21.43 billion, a P/E ratio of 17.88, a PEG ratio of 1.69 and a beta of 0.59.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating the consensus estimate of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The company had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. During the same quarter in the prior year, the company posted $6.41 EPS. United Therapeutics’s quarterly revenue was down 1.9% on a year-over-year basis. Equities analysts anticipate that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. JPMorgan Chase & Co. raised their price target on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Weiss Ratings raised shares of United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday. Royal Bank Of Canada lowered their target price on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Bank of America dropped their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research note on Friday, July 10th. Finally, Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $646.00.

Insiders Place Their Bets

In related news, EVP Paul A. Mahon sold 8,300 shares of the firm’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $517.05, for a total value of $4,291,515.00. Following the transaction, the executive vice president owned 45,172 shares of the company’s stock, valued at $23,356,182.60. This trade represents a 15.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $515.03, for a total transaction of $4,892,785.00. Following the sale, the chief executive officer owned 324,443 shares of the company’s stock, valued at $167,097,878.29. The trade was a 2.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 443,075 shares of company stock valued at $241,508,744 over the last three months. Insiders own 8.60% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.